Novelion Therapeutics Observes World Lipodystrophy Day
March 31, 2017 06:00 ET
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, March 31, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for...
Novelion Therapeutics’ Subsidiary Announces New Data to be Presented at the Annual Meeting of the Endocrine Society
March 30, 2017 16:15 ET
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new...
Novelion Therapeutics Reports Preliminary Fourth Quarter & Full Year 2016 Financial Results
March 15, 2017 07:00 ET
|
Novelion Therapeutics, Inc.
Company Reiterates FY 2017 Total Net Product Sales Expected to be Between $155 and $165 million Global Expansion Plans for Metreleptin Opportunity Underway VANCOUVER, British Columbia,...
Novelion Therapeutics to Announce Preliminary Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017
March 13, 2017 16:15 ET
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, March 13, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for...
Novelion Therapeutics Announces Presentation at the 29th Annual ROTH Conference
March 08, 2017 16:05 ET
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., March 08, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new...
U.S. Patent Trial and Appeal Board Affirms Lomitapide Patents with Favorable IPR Decisions
March 07, 2017 08:43 ET
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia & CAMBRIDGE, Mass., March 07, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new...
Novelion Therapeutics Announces Presentation at the Cowen and Company 37th Annual Health Care Conference
March 01, 2017 16:05 ET
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new...
Novelion Therapeutics Observes Rare Disease Day
February 28, 2017 08:05 ET
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new...
Novelion Therapeutics Announces Acceptance of Marketing Authorization Application for Metreleptin by European Medicines Agency
January 23, 2017 08:45 ET
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, Jan. 23, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for...
Novelion Therapeutics Reports Preliminary 2016 Net Product Sales and Provides 2017 Outlook
January 09, 2017 07:40 ET
|
Novelion Therapeutics, Inc.
- Company Reports Preliminary Total Net Product Sales Expected to be Between $150 million and $152 million, Exceeding High End of Prior Guidance - Global Expansion Plans for Metreleptin...